Abstract
PET-CT has no current role in the initial diagnosis of ovarian cancer. While imaging studies are not the basis of staging, imaging studies are often performed preoperatively (usually CT or MRI of the abdomen and pelvis) on patients suspected of advanced disease. A major advantage of PET-CT is the registered and aligned nature of the detailed anatomic images generated by the multidetector CT technology with the images of tissue metabolism possible by the PET technology. This allows for staging based on anatomic classification such as determining local extension of tumor into adjacent structures. Moreover, subtle metabolic abnormalities on FDG PET can be missed or misinterpreted as physiologic concentration of tracer, and the coregistration of the PET images with CT helps to further identify the lesion based on morphologic criteria.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.
FIGO Cancer Committee. The new FIGO stage grouping for primary carcinoma of the ovary (1985). Gynecol Oncol 1986;25:383.
Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, Mettlin CJ, Blake CA. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry (1981–1991). Cancer 1993;71:582–588.
Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331–338.
Rieber A, Nussle K, Stohr I, Grab D, Fenchel S, Kreienberg R, Reske SN, Brambs HJ. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 2001;177:123–129.
Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266–271.
Fenchel S, Grab D, Nussle K, Kotzerke J, Rieber A, Kreienberg R, Brambs HJ, Reske SN. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002;223:780–788.
Risum S, Hogdall C, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancer – a prospective study. Gynecol Oncol 2007;105(1):145–149.
American Cancer Society. Cancer facts and figures: 1998. Atlanta: American Cancer Society, 1998;13.
Kuhn W, Rutke S, Spathe K. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 2001;92:2585–2591.
Tempany CMC, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities. Report from the Radiological Diagnostic Oncology Group. Radiology 2000;215:761–767.
Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am J Roentgenol 2004;182:227–233.
Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol 2009;71(1):43–52.
Rubin SC, Hoskins WJ, Hakes TB, Markman M, Reichman BS, Chapman D, Lewis JL Jr. Serum CA125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989;160:667–671.
Kim EE. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Int J Gynecol Cancer 2004;14:12–22.
Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004;233:433–440.
Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 2008;33:112–118.
Poveda A. Ovarian cancer treatment: what is new? Int J Gynecol Cancer 2003;13:241–250.
Simcock B, Neesham D, Quinn M, et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103(1):271–276.
Patsner B. Is there a role for CT scanning to monitor therapy of optimally debulked patients with advanced ovarian epithelial cancer? Int J Gynecol Cancer 1994;4:19–21.
Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18 fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445–7453.
Risum S, Høgdall C, Loft A, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography – a prospective study. Gynecol Oncol 2008;108(2):265–270.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Buchpiguel, C.A. (2011). PET-CT of Ovarian Cancer. In: Shreve, P., Townsend, D. (eds) Clinical PET-CT in Radiology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-48902-5_25
Download citation
DOI: https://doi.org/10.1007/978-0-387-48902-5_25
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-48900-1
Online ISBN: 978-0-387-48902-5
eBook Packages: MedicineMedicine (R0)